Meeting
2024 ASCO Genitourinary Cancers Symposium
ProstACT GLOBAL: A phase 3 study of best standard of care with and without 177Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing metastatic castration-resistant prostate cancer progressing despite prior treatment with a novel androgen axis drug.
Authors
Charlotte Hawkins
Telix Pharmaceuticals, Fishers, IN
Charlotte Hawkins , Nat Lenzo , Julie Gibson , Tracey Brown , Neel Patel , Stefanie Martina , Colin Hayward
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04876651
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr TPS256)
DOI
10.1200/JCO.2024.42.4_suppl.TPS256
Abstract #
TPS256
Poster Bd #
Q17
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The impact of circulating tumor cell HOXB13 RNA detection in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide.
First Author: Siyuan S Guo
Poster
2021 Genitourinary Cancers Symposium
A phase III, randomized, open-label, study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy (NHT) in patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC).
First Author: Neeraj Agarwal
Poster
2021 Genitourinary Cancers Symposium
Significance of targeting the antiapoptotic pathway in castration-sensitive prostate cancer.
First Author: Goutam Chakraborty
Poster
2020 Genitourinary Cancers Symposium
Impact of upstream use of novel hormonal therapy on progression of patients (pts) to metastatic castration-resistant prostate cancer (mCRPC) in the United States (US).
First Author: Howard I. Scher